Leiden, the Netherlands, February 7, 2025: On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to the ...

Investors in Pharming Group N.V. (AMS:PHARM) had a good week, as its shares rose 2.2% to close at €0.98 following the release of its third-quarter results. Revenues were US$53m, approximately in line ...

6 analysts have expressed a variety of opinions on Pharming (NASDAQ:PHAR) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker believes has blockbuster potential with a type of mitochondrial disease. At the ...

With an infrastructure in place to market its lone commercial product Ruconest, it made sense in 2019 for Pharming Group to scoop up another rare disease candidate in the same arena. Four years later, ...

Novartis has acquired a priority review voucher from Pharming for the bargain price of $21.1 million, thanks to some shrewd dealmaking dating back a few years. The Dutch biotech was awarded the rare ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pharming (NASDAQ:PHAR) in the last three months. The following table provides a quick overview ...

When we look around, we are amazed at the speed with which the world is changing. Online fraud techniques such as Pharming and other cybercrime attacks are at an all-time high. To overcome such ...

A pharming attack tries to redirect a website’s traffic to a fake website controlled by the attacker, usually for the purpose of collecting sensitive information from victims or installing malware on ...